Status:
COMPLETED
Serum Vancomycin Levels in Patients Receiving Enteral Vancomycin
Lead Sponsor:
Maimonides Medical Center
Conditions:
Clostridium Difficle Colitis
Clostridium Difficle Associated Disease
Eligibility:
All Genders
18+ years
Brief Summary
The study is based on the hypothesis that decreased creatinine clearance may be associated with detectable vancomycin levels in patients on enteral (oral / vancomycin enemas) vancomyicn for CDAD. The...
Detailed Description
Vancomycin is a large glycopeptide compound with a molecular weight of about 1450 Da. It is not appreciably absorbed orally and is eliminated primarily via the renal route. Enteral vancomycin therapy ...
Eligibility Criteria
Inclusion
- Patients on enteral vancomycin therapy
Exclusion
- Coadministration of intravenous vancomycin therapy,intravenousvancomycin administration in previous10 days.
Key Trial Info
Start Date :
October 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2010
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00617227
Start Date
October 1 2007
End Date
February 1 2010
Last Update
February 10 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maimonides Medical Center
Brooklyn, New York, United States, 11219